soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Heart disease is the #1 cause of death in type 2 diabetes — and for the first time, an oral GLP-1 drug has been proven to reduce major cardiovascular events The SOUL

29.16

★★★★☆4.8 (126)

New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj Oral Semaglutide and Cardiovascular Outcomes (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis

25.03

★★★★★4.9 (98)

Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial

23.35

★★★★★5.0 (157)

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

22.85

★★★★★4.7 (84)

Journal club: SOUL Study – CVOT for Oral Semaglutide Full Title: Cardiovascular Outcomes Trial of Oral Semaglutide in Subjects with Type 2 Diabetes กองอายุรกรรม รพ พระมงกุฎเกล้า

27.72

★★★★★4.9 (203)

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

22.64

★★★★★5.0 (176)

🔴Notable Articles of 2024 ⤵️@NEJM 1. FLOW trial-Semaglutide into mainstream 🧑‍⚖️Semaglutide ⬇️reduced risks of kidney outcomes and death from CVS cause in pts with T2DM and CKD 2❣️FINEARTS-HF-MRAs in Heart Failure 🧑‍⚖️

28.30

★★★★★4.8 (132)